Anterogen.Co.Ltd
Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regen… Read more
Anterogen.Co.Ltd (065660) - Net Assets
Latest net assets as of September 2025: ₩90.04 Billion KRW
Based on the latest financial reports, Anterogen.Co.Ltd (065660) has net assets worth ₩90.04 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩91.44 Billion) and total liabilities (₩1.40 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩90.04 Billion |
| % of Total Assets | 98.46% |
| Annual Growth Rate | 23.86% |
| 5-Year Change | 35.95% |
| 10-Year Change | 562.36% |
| Growth Volatility | 30.98 |
Anterogen.Co.Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Anterogen.Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Anterogen.Co.Ltd (2014–2024)
The table below shows the annual net assets of Anterogen.Co.Ltd from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩110.21 Billion | -14.86% |
| 2023-12-31 | ₩129.44 Billion | +21.21% |
| 2022-12-31 | ₩106.79 Billion | -8.62% |
| 2021-12-31 | ₩116.87 Billion | +44.16% |
| 2020-12-31 | ₩81.07 Billion | +18.53% |
| 2019-12-31 | ₩68.39 Billion | +21.97% |
| 2018-12-31 | ₩56.07 Billion | +20.31% |
| 2017-12-31 | ₩46.61 Billion | +36.98% |
| 2016-12-31 | ₩34.02 Billion | +104.48% |
| 2015-12-31 | ₩16.64 Billion | +28.38% |
| 2014-12-31 | ₩12.96 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anterogen.Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 459682081000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩120.64 Billion | 109.46% |
| Total Equity | ₩110.21 Billion | 100.00% |
Anterogen.Co.Ltd Competitors by Market Cap
The table below lists competitors of Anterogen.Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Arnoldo Mondadori Editore S.p.A.
LSE:0KAV
|
$239.05 Million |
|
Wuhan Xingtu Xinke Electronics Co Ltd
SHG:688081
|
$239.06 Million |
|
Yanlord Land Group Limited
PINK:YLDGF
|
$239.09 Million |
|
Immobiliare Grande Distribuzione SIIQ SpA
LSE:0STP
|
$239.12 Million |
|
Hubei Forbon Technology Co Ltd
SHE:300387
|
$238.92 Million |
|
Blackline Safety Corp
PINK:BLKLF
|
$238.92 Million |
|
Orient Electric Limited
NSE:ORIENTELEC
|
$238.90 Million |
|
Tianjin Hi-Tech Development Co Ltd
SHG:600082
|
$238.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anterogen.Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 129,444,936,990 to 110,211,616,140, a change of -19,233,320,850 (-14.9%).
- Net loss of 2,292,835,490 reduced equity.
- Other factors decreased equity by 16,940,485,360.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-2.29 Billion | -2.08% |
| Other Changes | ₩-16.94 Billion | -15.37% |
| Total Change | ₩- | -14.86% |
Book Value vs Market Value Analysis
This analysis compares Anterogen.Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.18x to 4.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4558.73 | ₩46400.00 | x |
| 2017-12-31 | ₩5859.76 | ₩46400.00 | x |
| 2018-12-31 | ₩6643.89 | ₩46400.00 | x |
| 2019-12-31 | ₩7906.52 | ₩46400.00 | x |
| 2020-12-31 | ₩8914.81 | ₩46400.00 | x |
| 2021-12-31 | ₩12403.78 | ₩46400.00 | x |
| 2022-12-31 | ₩10973.93 | ₩46400.00 | x |
| 2023-12-31 | ₩13301.82 | ₩46400.00 | x |
| 2024-12-31 | ₩11325.39 | ₩46400.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anterogen.Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33.07%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.05x
- Recent ROE (-2.08%) is above the historical average (-3.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -10.92% | -77.18% | 0.13x | 1.12x | ₩-2.71 Billion |
| 2015 | -0.35% | -1.65% | 0.19x | 1.11x | ₩-1.72 Billion |
| 2016 | 1.09% | 7.59% | 0.14x | 1.04x | ₩-3.03 Billion |
| 2017 | 0.96% | 8.34% | 0.09x | 1.25x | ₩-4.21 Billion |
| 2018 | -1.72% | -26.66% | 0.04x | 1.81x | ₩-6.57 Billion |
| 2019 | -5.92% | -97.64% | 0.05x | 1.24x | ₩-10.89 Billion |
| 2020 | -5.40% | -105.39% | 0.04x | 1.16x | ₩-12.48 Billion |
| 2021 | -0.47% | -6.82% | 0.06x | 1.17x | ₩-12.24 Billion |
| 2022 | -6.40% | -103.73% | 0.05x | 1.16x | ₩-17.52 Billion |
| 2023 | -2.19% | -43.70% | 0.04x | 1.15x | ₩-15.79 Billion |
| 2024 | -2.08% | -33.07% | 0.06x | 1.05x | ₩-13.31 Billion |
Industry Comparison
This section compares Anterogen.Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $96,196,506,488
- Average return on equity (ROE) among peers: -9.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anterogen.Co.Ltd (065660) | ₩90.04 Billion | -10.92% | 0.02x | $238.93 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |